Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb - Research Grade
Source
CAS 2578319-11-4
Species
Homo sapiens
Expression system
XtenCHO
Molecular weight
143.8kDa
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Bebtelovimab,LY-CoV1404, LY3853113,SARS-CoV-2 Spike Protein,anti-SARS-CoV-2 Spike Protein
Reference
PX-TA1750
Note
For research use only. Not suitable for human use.
Isotype
IgG1,kappa
Clonality
Monoclonal Antibody
Description of Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb - Research Grade
Introduction to Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb
Bebtelovimab Biosimilar, also known as Anti-SARS-CoV-2 Spike Protein mAb, is a monoclonal antibody that has been developed as a therapeutic agent against the SARS-CoV-2 virus. This antibody specifically targets the spike protein of the virus, which is responsible for its entry into human cells. In this article, we will explore the structure, activity, and potential applications of Bebtelovimab Biosimilar in the fight against COVID-19.
Structure of Bebtelovimab Biosimilar
Bebtelovimab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in the laboratory using genetic engineering techniques. It is designed to mimic the structure of the human immune system’s natural antibodies, making it highly specific and effective in targeting the SARS-CoV-2 virus.
The antibody is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. Each chain contains variable regions, which are responsible for binding to the spike protein of the virus, and constant regions, which determine the antibody’s effector functions.
Activity of Bebtelovimab Biosimilar
Bebtelovimab Biosimilar works by binding to the spike protein of the SARS-CoV-2 virus, preventing it from attaching to the ACE2 receptor on human cells. This effectively blocks the virus from entering and infecting the cells, thus preventing the spread of the infection.
In addition, Bebtelovimab Biosimilar also activates the immune system’s response against the virus. When the antibody binds to the spike protein, it triggers a series of immune responses, including the activation of complement proteins and the recruitment of immune cells to the site of infection. This helps to further eliminate the virus and clear the infection.
Applications of Bebtelovimab Biosimilar
As a highly specific and potent antibody against the SARS-CoV-2 virus, Bebtelovimab Biosimilar has several potential applications in the fight against COVID-19.
Therapeutic Use: Bebtelovimab Biosimilar can be used as a therapeutic agent for treating patients with COVID-19. It can be administered as a standalone treatment or in combination with other antiviral drugs to improve its efficacy. The antibody has shown promising results in clinical trials, reducing the severity of symptoms and shortening the duration of the illness.
Prophylactic Use: Bebtelovimab Biosimilar can also be used as a prophylactic treatment for individuals who have been exposed to the virus or are at high risk of infection. By neutralizing the virus, the antibody can prevent the onset of the disease or reduce its severity in those who have been exposed.
Research Use: Bebtelovimab Biosimilar is also available in a research-grade format, which can be used by scientists and researchers to study the SARS-CoV-2 virus and develop new treatments and vaccines. The antibody can be used in various assays and experiments to understand the virus’s biology and its interaction with the human immune system.
Conclusion
Bebtelovimab Biosimilar, also known as Anti-SARS-CoV-2 Spike Protein mAb, is a recombinant humanized monoclonal antibody that specifically targets the spike protein of the SARS-CoV-2 virus. It works by blocking the virus’s entry into human cells and activating the immune system’s response against the infection. The antibody has potential applications in both therapeutic and prophylactic use, as well as in research to combat the COVID-19 pandemic. Its high specificity and potency make it a promising candidate in the fight against this global health crisis.
SDS-PAGE for Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb
Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Publication
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike, Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens, bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1, Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, Lisa Yuko Espinosa, Alex Samadi, Yuko Hiramoto, CJ Okumura, Toshiaki Maruyama, bioRxiv 2023.01.25.525589; doi: https://doi.org/10.1101/2023.01.25.525589
Melissa García-Vega, Edgar A. Melgoza-González, Sofía Hernández-Valenzuela, Harold Marcotte, Qiang Pan-Hammarström, Jesús Hernández et al., 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern, iScience, Volume 26, ISSUE 4, 106562, April 21, 2023, https://doi.org/10.1016/j.isci.2023.106562
Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168
De Cae, S., Van Molle, I., van Schie, L. et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat Commun 16, 5040 (2025). https://doi.org/10.1038/s41467-025-60250-1
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.